Type II Secretory Phospholipase A2 and Prognosis in Patients with Stable Coronary Heart Disease: Mendelian Randomization Study by Breitling, Lutz P. et al.
Type II Secretory Phospholipase A2 and Prognosis in
Patients with Stable Coronary Heart Disease: Mendelian
Randomization Study
Lutz P. Breitling
1*, Wolfgang Koenig
2, Marcus Fischer
3, Ziad Mallat
4, Christian Hengstenberg
3, Dietrich
Rothenbacher
1,5, Hermann Brenner
1
1Division C070 Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Department of Internal Medicine II-
Cardiology, University of Ulm Medical Center, Ulm, Germany, 3Klinik und Poliklinik fu ¨r Innere Medizin II, University of Regensburg, Regensburg, Germany, 4Division of
Cardiovascular Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom, 5Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany
Abstract
Background: Serum type II secretory phospholipase A2 (sPLA2-IIa) has been found to be predictive of adverse outcomes in
patients with stable coronary heart disease. Compounds targeting sPLA2-IIa are already under development. This study
investigated if an association of sPLA2-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or
mainly a matter of confounding by correlated cardiovascular risk markers.
Methodology/Principal Findings: Eight-year follow-up data of a prospective cohort study (KAROLA) of patients who
underwent in-patient rehabilitation after an acute cardiovascular event were analysed. Associations of polymorphisms (SNP)
in the sPLA2-IIa-coding gene PLA2G2A with serum sPLA2-IIa and secondary fatal or non-fatal CVD events were examined by
multiple regression. Hazard ratios (HR) were compared with those expected if the association between sPLA2-IIa and CVD
were causal. The strongest determinants of sPLA2-IIa (rs4744 and rs10732279) were associated with an increase of serum
concentrations by 81% and 73% per variant allele. HRs (95% confidence intervals) estimating the associations of the SNPs
with secondary CVD events were increased, but not statistically significant (1.16 [0.89–1.51] and 1.18 [0.91–1.52] per variant
allele, respectively). However, these estimates were very similar to those expected when assuming causality (1.18 and 1.17),
based on an association of natural log-transformed sPLA2-IIa concentration with secondary events with HR=1.33 per unit.
Conclusion: The present findings regarding genetic polymorphisms, determination of serum sPLA2-IIa, and prognosis in
CVD patients are consistent with a genuine causal relationship and thus might point to a valid drug target for prevention of
secondary CVD events.
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Introduction
Recent studies have demonstrated that the pro-inflammatory
enzyme type II secretory phospholipase A2 (sPLA2-IIa) provides
prognostic information beyond other established risk markers in
both primary [1,2] and secondary [3,4,5] cardiovascular disease
events. Further elucidating the causality of these associations would
be of outstanding and immediate relevance, as therapeutic agents
targeting sPLA2 are already under development [6,7]. However,
since cardiovascular risk factors tend to be closely correlated, it
remains unclear whether the associations reported to date reflect
genuine causality, or are spurious and due to imperfect adjustment
for confounding variables especially in observational studies.
As reviewed in detail elsewhere [8,9,10], several findings from
experimental studies would be consistent with a causal role of this
enzyme in atherosclerosis and cardiovascular disease. For
example, modifications by sPLA2-IIa contribute to the affinity of
low-density lipoproteins to extracellular proteoglycans, which can
ultimately result in higher extracellular lipoprotein accumulation,
an important component of atherogenesis [8]. Overexpression
experiments have further shown that macrophage sPLA2-IIa
contributes to oxidative stress and plays a role in foam cell growth
as well as in the development of atherosclerotic lesions at least in
mice [9,11].
Mendelian randomization is an approach in which the
magnitude of the presumably unconfounded association between
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22318genetic determinants of a risk marker and an outcome of interest
is employed to make inferences regarding the extent of causal
association between the marker and the disease [12,13,14]. If,
for instance, a genetic variant is associated with a doubling in
marker concentrations, and a doubling of marker concentra-
tions is associated with an x-fold elevation in risk, the genetic
variant should likewise be associat e dw i t ha nx - f o l dr i s ki n c r e a s e ,
but only if the marker–disease association is not due to
confounding. Otherwise, the genetic variant–disease association
should be weakened or even nil, since—similar to randomized
intervention allocation in clinical trials—the randomized
allocation of alleles during meiosis essentially ensures that no
association exists between the genetic variant and the con-
founders (known or unknown) commonly distorting the marker–
disease association.
In the present work, we investigated the association between
single nucleotide polymorphisms (SNP) in the coding gene
PLA2G2A and serum levels of sPLA2-IIa in a large cohort of
patients with stable coronary heart disease featuring eight years of
follow-up. Drawing upon the idea of Mendelian randomization,
we subsequently aimed to elucidate whether the previously
described association between sPLA2-IIa and secondary CVD
events was causal or predominantly due to confounding.
Methods
Ethics Statement
The study protocol was approved by the ethics committees of
the physicians’ chambers of Hessen and Baden-Wu ¨rttemberg, and
of the Universities of Ulm and Heidelberg. All study participants
gave written informed consent.
Study Design
Details of the study design have been reported previously
[15]. In brief, patients participating in an in-patient rehabilita-
tion programme after experiencing an acute cardiovascular
event (acute coronary syndrome, myocardial infarction, coro-
nary revascularization) were recruited in two specialized
rehabilitation clinics in the South and West of Germany from
January 1999 to May 2000. Only subjects aged 30–70 years
admitted within three months after their acute event were
included in the study.
Baseline data were obtained by standardized self-administered
questionnaires at the beginning of in-patient rehabilitation, and
complemented by extracting relevant data from hospital records,
including secondary diagnoses and drug prescriptions at discharge
from the rehabilitation programme. Active follow-up by mailed
standardized questionnaires was carried out after 1, 3, 4.5, 6 and 8
years. Information on secondary cardiovascular events (myocar-
dial infarction and stroke) was provided by the general
practitioners of the participants. If participants were deceased,
de-facto death certificates including the major cause of death were
obtained from Public Health authorities.
Laboratory Measurements
A fasting blood sample was taken at the end of the in-patient
rehabilitation and stored at 280uC until analysis. Serum
concentrations of sPLA2-IIa mass were determined using a
commercially available ELISA assay (Cayman Chemical Co.,
Ann Arbor, MI/USA) with a lower detection limit of about 0.3
ng/mL. In addition, sPLA2-IIa activity was determined using a
selective fluorometric assay [5].
Table 1. Baseline characteristics and sPLA2-IIa concentrations and activities in patients with stable coronary heart disease.
sPLA2-IIa concentration (ng/mL) sPLA2-IIa activity (nmol/mL/min)
Participant characteristic N % Median Inter-quartile range Median Inter-quartile range
Overall population
a 1012 100 2.50 1.45–4.86 1.21 0.93–1.58
Age at baseline 30–39 years 20 2 1.47 0.92–1.91 0.95 0.76–1.22
40–49 years 125 12 1.71 1.10–3.51 1.07 0.89–1.41
50–59 years 292 29 2.08 1.31–3.91 1.12 0.87–1.44
60–70 years 575 57 2.99 1.71–5.63 1.30 0.97–1.70
Sex Female 152 15 4.99 2.20–8.21 1.53 1.17–2.15
Male 860 85 2.33 1.39–4.20 1.16 0.91–1.51
Patient group Acute coronary syndrome 127 13 2.00 1.26–3.81 1.11 0.93–1.39
Coronary intervention 296 29 2.77 1.69–5.36 1.25 0.94–1.68
Myocardial infarction 589 58 2.48 1.40–4.68 1.21 0.92–1.57
Body mass index #25 kg/m
2 285 28 2.47 1.44–4.99 1.16 0.92–1.53
.25–30 kg/m
2 569 56 2.41 1.44–4.61 1.21 0.91–1.55
.30 kg/m
2 157 16 3.14 1.49–5.98 1.35 1.01–1.79
Disease history Diabetes mellitus 177 18 3.45 1.80–6.26 1.35 1.05–1.76
Hypertension 564 56 2.77 1.54–5.47 1.26 0.94–1.67
Discharge prescriptions ACE-inhibitor 535 53 2.63 1.46–4.81 1.22 0.90–1.60
Lipid-lowering drugs 780 77 2.33 1.41–4.47 1.19 0.92–1.53
Smoking history Never 316 31 2.51 1.48–5.49 1.24 0.94–1.66
Formerly 645 64 2.48 1.42–4.63 1.20 0.92–1.56
Currently 51 5 2.66 1.73–5.09 1.16 0.95–1.41
aN and percentages refer to the subjects with concentration measurements available. Activity measurements were missing for 22 of these.
doi:10.1371/journal.pone.0022318.t001
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gene coding for sPLA2-IIa, we selected validated SNPs with minor
allele frequencies above 5% for which working TaqMan assays
were available (rs876018, rs955587, rs4744, rs10732279,
rs3753827, rs11573156). Intergenic SNPs were chosen from
nearby well conserved regions (rs10799599, rs10916685,
rs818678). Genotyping was done using 59 exonuclease TaqManH
technology (Applied Biosystems, Foster City, CA, USA). For each
genotyping experiment 10 ng DNA was employed in a total
volume of 5 ml containing 1x TaqManH Genotyping Master Mix
(Applied Biosystems). PCR reaction with pre-designed TaqMan
genotyping assays (Applied Biosystems) and post-PCR endpoint
plate read was carried out according to the manufacturer’s
instructions on a Applied Biosystems 7900HT Real-Time PCR
System. Sequence Detection System software version 2.3 (Applied
Biosystems) was used to assign genotypes applying the allelic
discrimination test. DNA was genotyped with duplicates of
samples (20%) to assess genotype quality. No genotyping
discrepancies were detected. After checking for deviations from
Hardy-Weinberg equilibrium, haplotypes were estimated using the
software PHASE version 2.1.1 [16,17]. Linkage disequilibrium
plots were created using Haploview version 4 [18].
Statistical Analysis
Linear regression models adjusted for age and sex with the
natural logarithm (ln)-transformed sPLA2-IIa mass concentration
or activity as the dependent variable were used to estimate the
association of individual SNP genotypes with serum sPLA2-IIa.
Multi-locus models adjusted for age and sex were constructed by
stepwise selection from all SNPs in Hardy-Weinberg equilibrium,
using permissive entry and stay significance levels of P=0.4 and
P=0.6. The final model was then chosen as the one with the most
favourable predicted residual sum of squares from 10-fold cross-
validation (SAS procedure GLMSELECT [19]). The association
of genotypes with secondary CVD events (fatal or non-fatal
myocardial infarction or stroke) was assessed using Cox propor-
tional hazards models, likewise adjusted for age and sex. For
subjects free of secondary CVD events at follow-up, the survival
time was censored if treating practitioners could not be contacted
anymore.
Potential confounders of the genotype–disease relationship
included the following covariables: sex, age, smoking status,
diagnosis of acute myocardial infarction, diabetes, hypertension,
number of vessels affected, discharge prescriptions of beta-blocking
agents, ACE inhibitors, diuretics, lipid-lowering drugs and ASS,
body mass index, HDL-, LDL- and total cholesterol, triglycerides,
Lp-PLA2, interleukin-6, hsCRP, NT-proBNP, RBP-4, cystatin C,
adiponectin, and creatinine clearance. Testing was done by
Kruskal-Wallis (continuous variables) or x
2 test (categorical
variables).
The updated Cox proportional hazards regression model
estimating the association between sPLA2-IIa concentration or
activity and secondary cardiovascular events was adjusted for all
variables identified as important confounders or covariables in
previous detailed analyses based on 4-year follow-up of our cohort
[5], i.e. age (continuous), sex, smoking status, diagnosis of diabetes
and hypertension, study site, type of acute intervention, baseline
HDL- and LDL-cholesterol (continuous), discharge prescription of
lipid-lowering drugs, body mass index (continuous), and number of
affected vessels.
Mendelian Randomization Approach.. As both the
genotype–marker (regression estimate bgRm) and marker–disease
associations (regression estimate bmRd, hazard ratio = exp(bmRd))
were modelled based on ln-transformed sPLA2-IIa concentrations,
the expected association between genotypes and disease under the
assumption of no confounding could be directly calculated as
bgRd=bgRm6bmRd (expected hazard ratio = exp(bgRd)).
Confidence intervals for the expected hazard ratios were
obtained as described elsewhere [20]: assuming the regression
estimates to originate from normal distributions around their point
estimate and with their respective standard deviation, 1,000,000
combinations of bgRm and bmRd were drawn pseudo-randomly,
and the 2.5th and 97.5th percentiles of the resulting 1,000,000
hazard ratios were taken as empirical estimates of the 95%
confidence interval limits. Note that the Mendelian randomization
approach was restricted to sPLA2-IIa mass concentrations, as the
genetic determination of activity was somewhat less pronounced.
Statistical analyses were conducted using SAS [19]; the
empirical 95% confidence interval of the expected hazard
ratios was obtained using R [21]. Tests were two-sided with
alpha =0.05.
Results
The nine SNPs could be genotyped in 991 to 1,014 of 1,019
participants for whom follow-up information for the combined
outcome of fatal and non-fatal secondary CVD events was also
available (84.5% of 1,206 subjects originally included; in each
follow-up round, response rates for both patient and general
practitioner questionnaires were $93%). The subjects in the
present analysis set had a median (interquartile range) age of 61
(54–65) years and BMI of 26.6 (24.8–28.7) kg/m
2. The study
population included 85.1% males, and 58.3% had suffered an
acute myocardial infarction. Further baseline characteristics along
with sPLA2-IIa concentrations and activities are reported in
Table 1. The blood draw for sPLA2-IIa measurements took place
on average6standard deviation 43613 days after the acute event
or procedure in the acute care hospital, and sPLA2-IIa
concentration as well as activity showed a weak negative
correlation with the time between the event/procedure and the
blood draw (Spearman coefficients of 20.11 and 20.12,
respectively). As the time between the event/procedure and the
blood draw, which ranged from 16 to 110 days, was neither
significantly associated with any of the genotypes, nor with the risk
of secondary cardiovascular disease events, this variable was not
further considered or controlled for in the subsequent analyses.
Genetic Determinants of sPLA2-IIa Concentration and
Activity
The location of the genotyped SNPs relative to PLA2G2A is
depicted in Figure 1, along with linkage disequilibrium plots.
Minor allele frequencies generally in line with dbSNP information
were observed for all loci (Table 2). As can be seen in the table,
two SNPs mildly deviated from Hardy-Weinberg equilibrium.
Figure 1. Location of the single nucleotide polymorphisms genotyped in this study in relation to the PLA2G2A gene (Panel A) and
linkage disequilibrium patterns between the markers considered for haplotype estimation (Panels B and C). Panel A: depicted is
chromosome 1, 20174.5–20182.2 kb; not shown are rs10799599 at position 20167087 and rs818678 at position 20238917. Panels B and C: D’ values in
Haploview standard colouring scheme are shown in B, r
2 values in Haploview r
2 colouring scheme are shown in C. Haplotype blocks were identified
by Haploview’s confidence interval option.
doi:10.1371/journal.pone.0022318.g001
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demonstrated in Table 2, most of the SNPs were strongly
associated with sPLA2-IIa concentrations. Analysing ln-trans-
formed concentrations, which were approximately normally
distributed, the proportion of variance explained by individual
SNPs reached up to 16%. The strongest effect was observed in
rs4744 variant homozygotes, in whom sPLA2-IIa was increased by
almost 200% in comparison to wildtype homozygotes. Two- and
three-loci haplotypes constructed from the block1 and block2
SNPs (Figure 1B and 1C), respectively, were also significantly
associated with plasma sPLA2-IIa mass, but effect sizes were lower
than for rs4744 and rs10732279 individually (not shown). When
instead employing stepwise model selection and cross-validation,
the final model included rs4744 and rs10799599 (regardless of
whether additive or three-categorical genotype effects were
assumed), suggesting that these variants might exert independent
effects on sPLA2-IIa concentrations. The regression coefficients in
the additive final model were b=0.544 for rs4744 and b=–0.120
for rs10799599.
Table 3 shows the analoguous results for sPLA2-IIa activity.
Whereas there likewise were strongly significant assocations with
several of the SNPs, the explained variance and %-changes
associated with the genetic variants tended to be smaller than
in the case of the sPLA2-IIa concentrations. The final model
based on stepwise model selection and cross-validation included
rs4744 and rs10799599 in the three-categorical approach,
and additionally rs10732279 and rs818678 in the additive ap-
proach (brs4744=0.115, brs10799599=–0.062, brs10732279=0.091,
brs818678=–0.041).
There were no pronounced associations between the SNP
genotypes and any of the variables screened as potential
confounders (details not shown). Only 4 tests yielded p-values
below 0.05, namely for the associations between rs955587 and age
(Kruskal-Wallis P=0.028), rs3753827 and HDL-cholesterol
(Kruskal-Wallis P=0.018), and between rs818678 and HDL-
cholesterol (Kruskal-Wallis P=0.0033) and prescription of diuret-
ics (x
2 P=0.014). Note, that 9 SNPs were tested against 25
variables, i.e. 225 tests were considered.
Genetic Variants, sPLA2-IIa, and Secondary CVD Events
Until year 8 follow-up, 149 secondary cardiovascular events
occurred in the analysis population, including 49 and 41 non-fatal
myocardial infarctions and strokes, and 59 deaths with cardiovas-
cular major cause. The genotyped individuals contributed a total
of 6889.4 person-years with a median follow-up time of 8.1 years.
In Cox regression analysis adjusting for multiple covariates as
included in the 4-year follow-up model [5], a unit increase in ln-
transformed sPLA2-IIa concentrations was associated with an
elevated risk of adverse outcomes with a hazard ratio (HR; 95%
confidence interval) of 1.33 (1.09–1.63; P=0.0057). Additionally
exploring the association of the ln-transformed concentrations with
all-cause mortality (total number of deaths observed: 116) revealed
no significant association (HR=1.12 [0.89–1.41]). The results for
ln-transformed sPLA2-IIa activity were not statistically significant
(secondary cardiovascular events: HR=1.41 [0.94–2.11]; all-cause
mortality: HR=0.98 [0.64–1.53]).
Observed associations between PLA2G2A SNPs and secondary
cardiovascular events estimated by Cox proportional hazards
regression are shown in the upper part of Table 4, both based on
genotypic and additive codings of the SNPs. The confidence
intervals around the estimated SNP effects all included the Null
value of no association (HR=1). However, for the SNPs most
strongly associated with sPLA2-IIa concentrations, the hazard
ratios observed were intriguingly consistent with those expected
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(bottom of Table 4). This became particularly clear for the
statistically more stable additive models which are less affected by
fluctuations due to small stratum sizes. Using a genotype score
constructed from the two SNPs in the sPLA2-IIa concentration
stepwise selection regression model (score=number of rs4744
variant alleles + (20.120/0.544)6number of rs10799599 variant
alleles) as a predictor of secondary cardiovascular events yielded
similar results (HR=1.16 [0.91–1.47]; expected HR=1.17
[1.05–1.31]).
Discussion
In the present study of patients with stable coronary heart
disease at baseline, we found a strong determination of serum
sPLA2-IIa by PLA2G2A polymorphisms. Although the associations
of these polymorphisms with prognosis of eight years of follow-up
were not statistically significant, considerations along the lines of
Mendelian randomization suggested that the observations were
consistent with a causal association between sPLA2-IIa and
cardiovascular prognosis and made confounding factors a rather
unlikely cause for these patterns.
Genetic Determination of sPLA2-IIa
Pronounced associations of SNPs in PLA2G2A with concen-
trations of sPLA2-IIa have been reported previously [22]. As
these data had not been published during the planning phase/
SNP assay preparation of the present study, our SNP selection
was not informed by this previous report. However, there was
an overlap of three SNPs, for which results were consistent in
both studies (rs876018, rs3753827, rs11573156). Wootton et al.
[22] interpreted their haplotype analysis by suggesting that
additional loci not captured by their assays would also
contribute importantly to sPLA2-IIa concentrations. They
identified two predominant tagging-SNPs, and it appears
noteworthy that the one (rs11573156) located closer to the
strongest individual predictors in the present analysis (rs4744
and rs10732279) was not assigned to the same haplotype block
as these two SNPs, which had not been covered by Wootton
et al. We had excluded rs11573156 due to rather limited
deviation from Hardy-Weinberg equilibrium distribution, re-
gardless of which rs4744 and rs10732279 should be considered
as relevant candidates for causal loci in future studies of genetic
sPLA2-IIa determination. The multi-locus model selection
approach additionally highlighted rs10799599 as a potential
independent predictor of sPLA2-IIa activity in our study.
Importantly, the strong genetic determination of sPLA2-IIa
concentrations could furthermore be extended to sPLA2-IIa
activity, for which the genetic determination was found to be
only slightly less pronounced, and possibly somewhat more
complex as suggested by the results of the multi-locus models.
Mendelian Randomization Interpretation
Given the moderate number of secondary CVD events
available for the present analyses (137 to 149 depending on
the model), the lack of statistical significance in survival analyses
was not overly surprising. However, our findings appear
qualitatively very different from the rather disappointing results
recently obtained by Mendelian randomization approaches
pertaining to the role of C-reactive protein in the causation of
coronary heart disease [23,24,25] or diabetes [26]. For both
diseases entities, robust evidence for independent and prospec-
tive associations with C-reactive protein had been accumulated
through multiple observational studies (details in [25,26]). In
subsequent Mendelian randomization analyses, however, a
causal relationship seemed very unlikely. For example, with
expected odds ratios (95% confidence interval) of 1.20 (1.07–
1.38) [25] and 0.94 (0.94–0.95) [24], the observed odds ratios
were 1.01 (0.74–1.38) and 1.00 (0.97–1.02), respectively.
Whereas the difference in effect directions in the two cited
analyses is due to different codings, the general pattern notably
is the same, despite the second study including many more
individuals and yielding substantially narrower confidence
intervals. In contrast, the patterns in our study appeared to
resemble more the evidence presented e.g. for homocysteine
with stroke [20]. The starting point for Mendelian randomiza-
tion analysis in the case of homocysteine was rather similar to
the C-reactive protein associations mentioned above. However,
the expected odds ratio of 1.20 (1.10–1.31) was approximated
Table 3. Genetic determination of sPLA2-IIa activities.
Genotypic model (three-categorical) Additive model
Single nucleotide polymorphism (n) R
2 P
a D%
b (95% CI) D%
c (95% CI) D%
d (95% CI)
rs10799599 (974) 0.046 ,0.0001 211.7 (216.6 to 26.49) 224.5 (230.8 to 217.7) 212.7 (216.1 to 29.17)
rs876018 (967) 0.003 0.16 22.5 (28.50 to 3.80) 13.1 (25.21 to 34.9) 0.2 (24.99 to 5.75)
rs955587 (973) 0.011 0.0008 25.8 (211.7 to 0.57) 232.6 (252.4 to 24.40) 27.2 (212.8 to 21.27)
rs4744 (974) 0.109 ,0.0001 28.1 (21.3 to 35.2) 61.9 (43.2 to 83.0) 27.7 (22.2 to 33.5)
rs10732279 (986) 0.105 ,0.0001 24.8 (18.3 to 31.7) 60.7 (44.2 to 79.0) 25.8 (20.6 to 31.1)
rs3753827 (985) 0.020 ,0.0001 211.9 (217.1 to 26.34) 214.0 (220.5 to 27.04) 27.9 (211.4 to 24.29)
rs11573156 (979) 0.110 ,0.0001 28.2 (21.5 to 35.2) 61.0 (42.8 to 81.5) 27.6 (22.2 to 33.3)
rs10916685 (973) 0.003 0.21 24.5 (29.86 to 1.26) 25.2 (213.2 to 3.58) 23.2 (27.01 to 0.77)
rs818678 (963) 0.021 ,0.0001 27.3 (212.6 to 21.63) 217.7 (224.2 to 210.6) 28.8 (212.3 to 25.19)
aBased on non-parametric Kruskal-Wallis test on untransformed sPLA2-II activities.
bPercent change in geometric mean sPLA2-II activity in heterozygotes in reference to common homozygotes.
cPercent change in geometric mean sPLA2-II activity in rare homozygotes in reference to common homozygotes.
dPercent change in geometric mean sPLA2-II activity per minor allele present.
Proportion of variance in ln-transformed sPLA2-IIa serum activity explained by the SNPs studied (R
2; one-way ANOVA), and results from age- and sex-adjusted regression
models predicting ln-transformed sPLA2-IIa activities from genotypes.
doi:10.1371/journal.pone.0022318.t003
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association, which produced an estimate of 1.26 (1.14–1.40).
Mixed results in trials of homocysteine-lowering interventions,
of course, are a reminder of the potential difficulties in
translating such findings into effective treatments [27].
The homocysteine Mendelian randomization study was based
on pooled analyses of more than 10,000 participants [20], and the
C-reactive protein analyses estimated associations using data from
more than 100,000 subjects [24]. Such large-scale meta-analytic
approaches clearly would be preferable for drawing more definite
conclusions regarding the causality of sPLA2-IIa with respect to
prognosis in coronary heart disease patients. Unfortunately, the
absolute scarcity of data pertinent to the prognostic value of
genetic determinants of sPLA2-IIa levels at present is prohibitive in
this regard. Also, the prognostic value of sPLA2-IIa itself has been
investigated only by few studies to date, which, as has been
discussed previously [5], might have been biased towards enlarged
effect estimates due to small sample sizes.
Limitations of the Present Work
Apart from moderate statistical power, aggravated by some loss-
to-follow-up hardly avoidable in observational epidemiological
studies, another limitation of our study was the possibility of
participant self-selection due to voluntary study participation. In
addition, our study design with recruitment upon arrival in the
rehabilitation clinic precluded the analysis of early mortality;
nevertheless, the study population represents the group that would
benefit from secondary prevention means. As associations and
causal relationships could plausibly differ between the early/acute
and late/chronic disease phases, the former should not be
considered the subject of the KAROLA study. Altogether, these
issues should not affect the internal validity of our findings, and
our analysis population indeed can still be considered represen-
tative for a substantial proportion of patients with stable coronary
heart disease. Finally, results from the present work were based on
a mostly male study population, and sex-specific aspects of the
relationships described need to be addressed in additional cohorts.
The absence of confounding of the genetic polymorphism–
disease association is one of the assumptions for valid Mendelian
randomization analyses [12]. While this usually is ensured due to
the random allocation of alleles during meiosis, which lies at the
core of the Mendelian randomization concept, the situation might
be somewhat different in studies of secondary CVD event, where
genotypes associated with higher risk for primary manifestations
may introduce some selection bias and compromise the naturally
occurring randomization. However, when we examined associa-
tions between the SNPs and a multitude of variables that have
previously been reported to be associated with cardiovascular risk,
only four P-values were smaller than 0.05. Given the multiplicity
of testing in this part of the analysis, these results made it unlikely
that the SNPs–secondary CVD events relationship was distorted to
any relevant degree by confounding due to known risk factors.
Conclusions and Perspective
Confirmatory studies are clearly needed to corroborate our
results. However, our findings are consistent with the prospect of
sPLA2-IIa being a ‘chicken’ rather than just another ‘egg’ with
respect to cardiovascular disease, very much in contrast to C-
reactive protein [28]. Given the global burden of morbidity and
mortality imposed by cardiovascular disease, such hints to
plausible causal relationships are of utmost importance and of
immediate relevance to future research priorities. Whereas the
investigation of clinical interventions with existing or yet-to-be-
developed sPLA2-IIa-inhibiting drugs [6,7] will necessarily be the
realm of randomized clinical trials, the present results strengthen
the pathophysiological rationale for conducting such studies. In
particular given the disappointing tale of causality and Mendelian
randomization of C-reactive protein, it furthermore appears
reasonable to include the most important genetic determinants
of sPLA2-IIa in any forthcoming studies of the prognostic value of
this marker, in order to capitalize on Mendelian randomization
from the beginning on.
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Table 4. Observed and expected relative risks.
Genotype HR
a (95% CI) HR
b (95% CI)
Observed
associations
rs10799599 CC 1 ref. 1 ref.
CG 0.88 (0.62–1.23) 0.85 (0.67–1.09)
GG 0.71 (0.40–1.24)
rs876018 AA 1 ref. 1 ref.
AT 1.24 (0.87–1.78) 1.11 (0.82–1.50)
TT 0.76 (0.24–2.40)
rs4744 GG 1 ref. 1 ref.
GA 1.09 (0.77–1.53) 1.16 (0.89–1.51)
AA 1.52 (0.79–2.93)
rs10732279 TT 1 ref. 1 ref.
TC 1.04 (0.74–1.46) 1.18 (0.91–1.52)
CC 1.65 (0.94–2.93)
rs3753827 CC 1 ref. 1 ref.
CA 0.71 (0.50–1.02) 0.89 (0.71–1.13)
AA 0.87 (0.56–1.35)
rs10916685 AA 1 ref. 1 ref.
AT 0.83 (0.59–1.17) 0.91 (0.72–1.16)
TT 0.92 (0.55–1.54)
rs818678 CC 1 ref. 1 ref.
CT 1.03 (0.72–1.47) 1.03 (0.81–1.30)
TT 1.06 (0.65–1.74)
Expected
associations
rs4744 GG 1 ref. 1 ref.
GA 1.20 (1.05–1.37) 1.18 (1.05–1.34)
AA 1.37 (1.09–1.74)
rs10732279 TT 1 ref. 1 ref.
TC 1.18 (1.05–1.33) 1.17 (1.05–1.31)
CC 1.35 (1.09–1.70)
aGenotypic model (three-categorical), adjusted for age and sex.
bAdditive genotype model, adjusted for age and sex.
Observed associations of individual SNPs with secondary cardiovascular events
(hazard ratios [HR] from Cox regression), and effects expected by Mendelian
randomization if the fully adjusted ln[sPLA2-IIa] association of HR (95% CI)
=1.33 (1.09–1.63) is not due to confounding.
doi:10.1371/journal.pone.0022318.t004
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